Epigenetic silencing of DSC3 is a common event in human breast cancer

Breast Cancer Research

Table 1 Summary of DSC3 expression and methylation state in primary breast tumors

Cell/tumor	Expression^a	Methylation^b	%Me^c	Age (years)	Histology
HMEC	100.0%	-	15	N/A	N/A
MCF10A	150.0%	-	7	N/A	N/A
120T	81.4%	-	3	59	IDC
7732T	6.9%	-	10	44	IDC
6385T	0.0%	++	69	70	IDC
173T	0.1%	+	30	55	IDC
8900T	77.2%	-	2	56	IDC
4658T	52.4%	-	8	83	IDC
7768T	2.3%	-	7	40	IDC
2504T	67.8%	-	16	53	IDC
9613T	8.0%	-	9	42	IDC
6010T	0.3%	+	21	55	IDC
2909T	26.3%	-	1	38	IDC
2845T	0.0%	++	49	77	IDC
^d5974-1T	10.0%	+	23	43	IDC
^d5974-2T	10.0%	++	48	43	IDC
7093T	10.0%	+	30	63	IDC
9068T	0.0%	-	8	73	IDC
4392T	0.0%	+	33	47	IDC
5799T	0.0%	+	22	53	IDC
6245T	0.0%	-	1	30	IDC
2405T	30.0%	+	20	58	IDC
2420T	0.0%	-	8	54	IDC
5256T	3.9%	-	1	60	IDC
1139T	6.4%	-	11	40	IDC lymph node Met.
9663T	0.1%	+	60	41	IDC lymph node Met.
9985T	5.8%	-	0	61	ILC
7788T	1.3%	+	23	76	ILC
6861T	20.2%	+	29	71	ILC
5358T	73.9%	++	58	42	ILC
6608T	5.6%	-	8	74	ILC
7491T	30.0%	-	2	64	ILC
6809T	0.0%	++	49	57	ILC
4099T	0.6%	+	37	43	Mucoid ductal CA

^aRNA expression levels determined by quantitative real-time PCR and relative to human mammary epithelial cells (HMECs). ^bCpG island methylation levels determined by bisulfite sequencing: ++, >40% methylation of total CpG sites analyzed; +, >20% methylation of total CpG sites; -, <20% methylation of total CpG sites analyzed. ^cPercent methylation was calculated based on the number of methylated CpG sites compared to the total number of sites analyzed. ^dTwo independent tumors isolated from the same breast. IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; N/A, not applicable, IDC lymph node Met, invasive ductal carcinoma that metastasized to the lymph node, Mucoiod Ductal CA, mucinous ductal carcinoma.

ISSN: 1465-542X